Production of Cytokine-Specific Monoclonal Antibodies that Modulate Immune and Inflammatory Processes.
Abstract
The goal of this cooperative agreement is to generate, characterize and produce substantial quantities of monoclonal antibodies (mAb) that enhance protective actions of murine cytokines. During the past funding period, we have used roller bottle and bioreactor tissue culture techniques and large scale HPLC Protein A affinity chromatography techniques to establish effective scale-up procedures that have resulted in the purification to homogeneity of 200+ mg quantities of mAb in aggregate and endotoxin free form. Four hundred mg of assorted purified mAb have already been provided to the Army for research purposes. This accomplishment thereby completes the first specific aim of the project. In addition, a new family of hamster mAbs have been generated that are specific for either the p55 or p75 murine TNF receptors. Within this family of antibodies are mAb the either inhibit or mimic TNF action i.e. which function either as TNF antagonists or agonists. These antibodies have been partially characterized using standard laboratory protocols and currently are being tested for beneficial protective effects in murine model systems. This result thus places us well along in completing the second specific aim thereby putting us right on schedule for the overall project. Antibody, Immunomodulation, BD, RAD IV
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 15, 1994
- Accession Number
- ADA282384
Entities
People
- Robert D. Schreiber
Organizations
- University of Washington